Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pacing technique may protect heart function in AFib patients

NCT ID NCT07428967

Disease control Sponsor: St. Josefs-Hospital Wiesbaden GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two types of pacemaker placement after a procedure called AV node ablation for people with atrial fibrillation and normal heart function. One method uses standard right ventricular pacing, while the other targets the left bundle branch area. The goal is to see which approach better preserves the heart's pumping ability and improves quality of life. About 86 participants will be randomly assigned to one of the two pacing methods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pacemaker implantation (left bundle branch area pacing vs. right ventricular pacing)
What this could lead to
If successful, this could offer a safer pacing method for people with atrial fibrillation, reducing the risk of heart muscle weakening after AV node ablation.
What could go wrong
This is a relatively small, early-stage trial (86 participants) comparing two procedures, so results may not apply to everyone. Both procedures carry standard risks of pacemaker implantation, such as infection or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 86 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. History of symptomatic AF (EHRA IIb - IV) despite guideline-indicated medical or interventional therapy 2. Preserved LVEF (≥ 50%, assessed by echocardiography, Simpson's biplane method) 3. AV node ablation scheduled independently of possible study participation 4. Age ≥ 18 years 5. Consent capacity Exclusion Criteria: 1. Impaired LVEF (\< 50%) 2. Pre-implanted pacemaker 3. Contraindication for pacemaker implantation or AV node ablation (see chapter 5.3 for details) 4. High grade (III°) left cardiac valvular disease 5. Surgical coronary revascularization (within the last 30 days) or current triple therapy after stent PCI 6. Body-mass-index \> 40 kg/m2 7. Pregnancy 8. Inability to give written informed consent 9. Life expectancy \< 12 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial arrhythmia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial arrhythmia Atrial fibrillation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Evangelisches Krankenhaus Hagen-Haspe

    NOT_YET_RECRUITING

    Hagen, Germany

  • St. Josefs-Hospital Wiesbaden GmbH

    RECRUITING

    Wiesbaden, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.